SCHEMBL2279274

SCHEMBL2279274

COCC(=O)Nc1cccc(C=CC(=O)c2c(O)cc(C)n(C)c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.41
CYP2C19 P33261 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ABCG2 Q9UNQ0 3/20 0.41
MMP1 P03956 3/20 0.40
MMP2 P08253 3/20 0.40
MMP9 P14780 3/20 0.40
KCNA3 P22001 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12374658 1.00 NPC1 (0.48) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2278735 0.90 ABCG2 (0.46) KMT2AMEN1SMN1; SMN2POLBGAA
SCHEMBL2275829 0.86 NPC1 (0.50) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2275832 0.86 NPC1 (0.50) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2280459 0.86 RAB9A (0.48) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2280461 0.86 RAB9A (0.48) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2275784 0.83 LMNA (0.43) KMT2AMEN1SMN1; SMN2POLBGAA
SCHEMBL12374657 0.83 LMNA (0.43) KMT2AMEN1SMN1; SMN2POLBGAA
SCHEMBL2277182 0.83 HDAC3 (0.50) NPC1RAB9AKMT2AMEN1POLB
SCHEMBL2277187 0.83 HDAC3 (0.50) NPC1RAB9AKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 NPC1 1610/4885RAB9A 3791/4885KMT2A 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.